Cantor Fitzgerald Maintains Overweight on Beam Therapeutics, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Rick Bienkowski has maintained an Overweight rating on Beam Therapeutics (NASDAQ:BEAM) but lowered the price target from $56 to $32.
October 17, 2023 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Beam Therapeutics but lowered the price target from $56 to $32.
The lowering of the price target by Cantor Fitzgerald from $56 to $32 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Beam Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100